Natera, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven Leonard Chapman
- Full Time Employees
- 6,140
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 13011 McCallen Pass Building A Austin TX United States of America 78753
- IPO Date
- Jul 1, 2015
- CIK
- 0001604821
- Website
- natera.com
- Similar Companies
- Business
- Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.
Beaconlight Capital LLC Raises Position in Natera, Inc. $NTRA
Natera, Inc. $NTRA Shares Purchased by Arrowstreet Capital Limited Partnership
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Natera, Inc. $NTRA Shares Sold by California Public Employees Retirement System
Fifth Third Bancorp Acquires 10,929 Shares of Natera, Inc. $NTRA
Amova Asset Management Americas Inc. Has $84.69 Million Stake in Natera, Inc. $NTRA
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?
Allspring Global Investments Holdings LLC Acquires 8,979 Shares of Natera, Inc. $NTRA
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera, Aveta partner on late-stage head and neck cancer trial
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial